|
顯示項目 615426-615475 / 2348971 (共46980頁)
<< < 12304 12305 12306 12307 12308 12309 12310 12311 12312 12313 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
1983 |
Nitrous Oxide in the Sea Off Southern California
|
劉康克; Kaplan, I. R.; Liu, Kon-Kee; Kaplan, I. R. |
| 國立臺灣大學 |
1996 |
Nitrous Oxide or Halothane, or Both, Fail to Suppress C-Fos Expression in Rat Spinal Cord Dorsal Horn Neurones after Subcutaneous Formalin
|
孫維仁; 謝長堯; SUN, WEI-ZEN; HSIEH, CHANG-YAO |
| 臺大學術典藏 |
2018-09-10T05:48:07Z |
Nitrous oxide or halothane, or both, fail to suppress c-fos expression in rat spinal cord dorsal horn neurones after subcutaneous formalin
|
Sun, W.-Z.;Shyu, B.C.;Shieh, J.Y.; Sun, W.-Z.; Shyu, B.C.; Shieh, J.Y.; WEI-ZEN SUN |
| 國立臺灣大學 |
2003 |
Nitrous Oxide Suppresses Tonic and Phasic Nociceptive Behaviors but Not Formalin-Induced C-Fos Expression in the Rat Spinal Cord Dorsal Horn
|
林峰盛; 徐百川; 謝正勇; 孫維仁; LIN, FENG-SHENG; SHYU, BAI-CHUANG; SHIEH, JENG-YUNG; SUN, WEI-ZEN |
| 臺大學術典藏 |
2018-09-10T04:26:16Z |
Nitrous oxide suppresses tonic and phasic nociceptive behaviors but not formalin-induced c-Fos expression in the rat spinal cord dorsal horn
|
Lin, F.-S.; Shyu, B.-C.; Shieh, J.-Y.; Sun, W.-Z.; WEI-ZEN SUN |
| 國立臺灣大學 |
2003-12 |
Nitrous oxide suppresses tonic and phasic nociceptive behaviors but not formalin-induced c-Fos expression in the rat spinal cord dorsal horn.
|
Lin, Feng-Sheng; Shyu, Bai-Chung; Shieh, Jeng-Yung; Sun, Wei-Zen |
| 臺北醫學大學 |
2014 |
Nitroxidative chemistry interferes with fluorescent probe chemistry: implications for nitric oxide detection using 2,3-diaminonaphthalene
|
TM, Hu;SJ, Chiu;YM, Hsu |
| 臺北醫學大學 |
2014 |
Nitroxidative chemistry interferes with fluorescent probe chemistry: implications for nitric oxide detection using 2,3-diaminonaphthalene
|
Hu, TM;Chiu, SJ;Hsu, YM |
| 臺北醫學大學 |
2014 |
Nitroxidative chemistry interferes with fluorescent probe chemistry: Implications for nitric oxide detection using 2,3-diaminonaphthalene
|
Hu, Teh-Min;Chiu, Shih-Jiuan;Hsu, Yu-Ming |
| 臺大學術典藏 |
2021-08-05T02:38:55Z |
Nitroxide polymer gels for recyclable catalytic oxidation of primary alcohols to aldehydes
|
Xie Y;Zhang K;Yamauchi Y;Jia Z.; Xie Y; Zhang K; Yamauchi Y; Jia Z.; KEVIN CHIA-WEN WU |
| 臺大學術典藏 |
2021-08-05T02:38:55Z |
Nitroxide radical polymers for emerging plastic energy storage and organic electronics: Fundamentals, materials, and applications
|
Xie Y;Zhang K;Yamauchi Y;Oyaizu K;Jia Z.; Xie Y; Zhang K; Yamauchi Y; Oyaizu K; Jia Z.; KEVIN CHIA-WEN WU |
| 國立臺灣大學 |
1993 |
Nitroxyl Free Radical Enhancement of the Forbidden O2[3Σg-]←O2(1Δg) Radiative Transition in Chlorinated Hydrocarbon Solvents
|
Belford, R. E.; Seely, G.; Gust, D.; Moore, T. A.; Moore, A.; Cherepy, N. J.; Ekbundit, S.; Lewis, J. E.; 林聖賢; Belford, R. E.; Seely, G.; Gust, D.; Moore, T. A.; Moore, A.; Cherepy, N. J.; Ekbundit, S.; Lewis, J. E.; Lin, Sheng-Hsien |
| 國家衛生研究院 |
2017-02 |
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial
|
Kang, YK;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Boku, N;Chen, LT |
| 臺大學術典藏 |
2022-08-19T00:20:37Z |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M.; Ikeda M.; Chopra A.; Numata K.; Yeo W.; Kang Y.-K.; Hou M.-M.; Kim T.-Y.; Choo S.-P.; CHIUN HSU; Yau T. |
| 臺大學術典藏 |
2019 |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Cruz C.D.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M. |
| 國家衛生研究院 |
2017-12 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang, YK;Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Chen, LT |
| 臺大學術典藏 |
2021-01-28T01:06:21Z |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang Y.-K.;Boku N.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Chen L.-T.; Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. |
| 臺大學術典藏 |
2017 |
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
|
El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; CHIUN HSU; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L.; Neely J.; Tang H.; Dastani H.B.; Melero I. |
| 臺大學術典藏 |
2020-04-10T12:51:02Z |
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
|
Melero I.; Dastani H.B.; Tang H.; Neely J.; El-Khoueiry A.B.;Sangro B.;Yau T.;Crocenzi T.S.;Kudo M.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Trojan J.;Welling T.H.;3Rd, Meyer T.;Kang Y.-K.;Yeo W.;Chopra A.;Anderson J.;Dela Cruz C.;Lang L.;Neely J.;Tang H.;Dastani H.B.;Melero I.; El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L. |
| 國家衛生研究院 |
2021-03-20 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Nishiyama, T;Chen, LT;Kang, YK |
| 臺大學術典藏 |
2022-01-05T03:36:39Z |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. |
| 國立成功大學 |
2021 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Nishiyama, T.;Chen, L.-T.;Kang, Y.-K. |
| 國家衛生研究院 |
2024-08-20 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri
|
Boku, N;Omori, T;Shitara, K;Sakuramoto, S;Yamaguchi, K;Kato, K;Kadowaki, S;Tsuji, K;Ryu, MH;Oh, DY;Oh, SC;Rha, SY;Lee, KW;Chung, IJ;Sym, SJ;Chen, LT;Chen, JS;Bai, LY;Nakada, T;Hagihara, S;Makino, R;Nishiyama, E;Kang, YK |
| 國立成功大學 |
2024-11 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri
|
Boku;Narikazu;Omori;Takeshi;Shitara;Kohei;Sakuramoto;Shinichi;Yamaguchi;Kensei;Kato;Ken;Kadowaki;Shigenori;Tsuji;Kunihiro;Ryu;Min-Hee;Oh;Do-Youn;Oh;Cheul, Sang;Rha;Young, Sun;Lee;Keun-Wook;Chung;Ik-Joo;Sym;Jin, Sun;Chen;Li-Tzong;Chen;Jen-Shi;Bai;Li-Yuan;Nakada;Takashi;Hagihara;Shunsuke;Makino;Reina;Nishiyama;Eiji;Kang;Yoon-Koo |
| 國立成功大學 |
2024 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3�tri
|
Boku;N;Omori;T;Shitara;K;Sakuramoto;S;Yamaguchi;K;Kato;K;Kadowaki;S;Tsuji;K;Ryu;M, -H.;Oh;D, -Y.;Oh;S, C.;Rha;S, Y.;Lee;K, -W.;Chung;I, -J.;Sym;S, J.;Chen;L, -T.;Chen;J, -S.;Bai;L, -Y.;Nakada;T;Hagihara;S;Makino;R;Nishiyama;E;Kang;Y, -K. |
| 國家衛生研究院 |
2020-09 |
Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
|
Boku, N;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2022-02 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr
|
Kang, YK;Chen, LT;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Oh, SY;Choda, Y;Yasui, H;Takeuchi, K;Hirashima, Y;Hagihara, S;Boku, N |
| 國立成功大學 |
2022 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-contr
|
Kang, Y.-K.;Chen, L.-T.;Ryu, M.-H.;Oh, D.-Y.;Oh, S.C.;Chung, H.C.;Lee, K.-W.;Omori, T.;Shitara, K.;Sakuramoto, Sakuramoto S.;Chung, I.-J.;Yamaguchi, K.;Kato, Kato K.;Sym, Sym S.J.;Kadowaki, S.;Tsuji, K.;Chen, J.-S.;Bai, L.-Y.;Oh, S.-Y.;Choda, Y.;Yasui, H.;Takeuchi, K.;Hirashima, Y.;Hagihara, S.;Boku, N. |
| 國家衛生研究院 |
2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome
|
Su, YY;Lin, YJ;Hsiao, CF;Ou, DL;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Lee, WC;Chou, SC;Ho, CL;Chiu, CF;Chen, LT;Shen, YS;Cheng, AL;Hsu, C |
| 國家衛生研究院 |
2021-07 |
Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma
|
Su, Y;Lin, Y;Hsiao, C;Ou, D;Chen, S;Wu, Y;Lee, W;Lin, J;Hsu, C;Ho, M;Lu, L;Wu, T;Lai, S;Chao, Y;Chou, T;Yen, C;Chen, L;Shan, Y;Cheng, A;Hsu, C |
| 國家衛生研究院 |
2025-09-17 |
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration
|
Lin, YJ;Ou, DL;Su, YY;Hsu, CL;Hsiao, CF;Ko, BS;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Jeng, YM;Lee, WC;Chou, SC;Chen, TW;Chiu, CF;Shiuan, L, Jr.;Hsieh, CH;Lee, CC;Shen, YS;Cheng, AL;Chen, LT;Hsu, C |
| 臺大學術典藏 |
2020-07-21T06:46:14Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.; Chih-Hsin Yang J.; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; CHAO-CHI HO; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T02:50:35Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.;Chih-Hsin Yang J.;Su W.-C.;Chong I.-W.;Hsia T.-C.;Lin M.-C.;Chang G.-C.;Chiu C.-H.;Chao-Chi Ho;Wu S.-Y.;Hung J.-Y.;Wang C.-C.;Yang T.-Y.;Yu C.-J.; Chen Y.-M.; Chih-Hsin Yang J.; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; CHAO-CHI HO; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T06:34:14Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.;Chih-Hsin Yang J.;Su W.-C.;Chong I.-W.;Hsia T.-C.;Lin M.-C.;Chang G.-C.;Chiu C.-H.;Ho C.-C.;Wu S.-Y.;Hung J.-Y.;Wang C.-C.;Yang T.-Y.;Chong-Jen Yu; Chen Y.-M.; Chih-Hsin Yang J.; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; Ho C.-C.; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2022-06-27T06:59:40Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.; Chih-Hsin Yang J.; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; Ho C.-C.; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2022-08-10T02:37:42Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.; CHIH-HSIN YANG; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; Ho C.-C.; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; Yu C.-J. |
| 國立成功大學 |
2020 |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen, Y.-M.;Chih-Hsin, Yang J.;Su, W.-C.;Chong, I.-W.;Hsia, T.-C.;Lin, M.-C.;Chang, G.-C.;Chiu, Chiu C.-H.;Ho, C.-C.;Wu, S.-Y.;Hung, J.-Y.;Wang, C.-C.;Yang, T.-Y.;Yu, C.-J. |
| 國家衛生研究院 |
2018-05 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
|
Chau, I;Chen, LT;Kang, YK;Satoh, T;Kato, K;Chung, HC;Kang, WK;Chao, Y;Chen, JS;Ott, PA;Le, DT;Zhao, HY;Jimenez-Exposito, MJ;Janjigian, YY;Boku, N |
| 國家衛生研究院 |
2018-02 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
|
Chau, I;Chen, LT;Kang, YK;Satoh, T;Kato, K;Chung, HC;Kang, WK;Chao, Y;Chen, JS;Ott, PA;Le, DT;Zhao, H;Jimenez-Exposito, MJ;Janjigian, YY;Boku, N |
| 國家衛生研究院 |
2018-09 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
|
Haag, GM;Chen, LT;Kang, YK;Satoh, T;Kato, K;Chung, HC;Kang, WK;Chao, Y;Chen, JS;Ott, PA;Le, DT;Zhao, H;Exposito, MJJ;Janjigian, YY;Boku, N;Chau, I |
| 臺大學術典藏 |
2020-04-28T07:25:09Z |
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
|
Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y.; Kato K.;Cho B.C.;Takahashi M.;Okada M.;Lin C.-Y.;Chin K.;Kadowaki S.;Ahn M.-J.;Hamamoto Y.;Doki Y.;Yen C.-C.;Kubota Y.;Kim S.-B.;Chih-Hung Hsu;Holtved E.;Xynos I.;Kodani M.;Kitagawa Y. |
| 淡江大學 |
1992-06 |
Nixon Probes America's Challenge: Sole Superpower in the Post-Cold War Era -- A Featured Commentary
|
Trimarchi, Anthony George |
| 淡江大學 |
1992-06 |
Nixon's Latest : Charting America's global future
|
崔馬吉; Trimarchi, Anthony George |
| 淡江大學 |
2003-07 |
Nixon's visit to the China mainland in 1972 : A review of brezhnev's response after three decades
|
戴萬欽; Tai, Wan-chin |
| 臺大學術典藏 |
2021-08-05T02:38:55Z |
Ni–Co Binary Hydroxide Nanotubes with Three-Dimensionally Structured Nanoflakes: Synthesis and Application as Cathode Materials for Hybrid Supercapacitors
|
Dai Z;Lin J;Dong Q;Yin Z;Zang X;Shen L;Kim J.H;Huang W;Alshehri S.M;Young C;Yamauchi Y;Dong X.; Dai Z; KEVIN CHIA-WEN WU et al. |
| 義守大學 |
2003 |
Ni、Cr、Mo對鑄造SKT4工具鋼顯微組織與機械性質之影響
|
曾文生; Wen-Sheng Tseng |
| 國立成功大學 |
2016-08-24 |
Ni添加對Sn-1 5Ag-0 7Cu低銀無鉛銲料顯微組織與機械性質影響之研究
|
謝喻丞; Hsieh, Yu-Chen |
| 國立成功大學 |
2017-08-25 |
Ni添加對Sn-1 5Ag-0 7Cu無鉛銲料低週疲勞破壞及時效影響之研究
|
洪瑞隆; Hung, Jui-Lung |
| 國立成功大學 |
2016-07-28 |
Ni添加對Sn-1.5Ag-0.7Cu低銀無鉛銲料顯微組織與機械性質影響之研究
|
謝喻丞; Hsieh, Yu-Chen |
| 國立成功大學 |
2017-07-27 |
Ni添加對Sn-1.5Ag-0.7Cu無鉛銲料低週疲勞破壞及時效影響之研究
|
洪瑞隆; Hung, Jui-Lung |
顯示項目 615426-615475 / 2348971 (共46980頁)
<< < 12304 12305 12306 12307 12308 12309 12310 12311 12312 12313 > >>
每頁顯示[10|25|50]項目
|
